Classes
DEA Class; Rx
Common Brand Names; Teveten HCT, Teveten Plus
- ARB/HCTZ Combos
Description
Angiotensin II antagonist and thiazide diuretic used together for management of HTN; additive efficacy; less potassium loss compared to diuretic monotherapy.
Indications
Indicated for the treatment of hypertension in patients who do not respond to monotherapy.
Contraindications
Hypersensitivity to eprosartan, hydrochlorothiazide, or sulfonamides
Pregnancy (2nd/3rd trimesters): Significant risk of fetal/neonatal morbidity and mortality
Anuria
Do not coadminister with aliskiren in patients with diabetes mellitus
Adverse Effects
Adverse reactions with combination products and individual agents
Decreased neutrophil count (1%)
Back pain (3%)
Increased BUN (1%)
Eprosartan
- Upper respiratory infection (8%)
- Cough (4%)
- Abdominal pain (2%)
- Fatigue (2%)
- Hypertriglyceridemia (1%)
- Urinary tract infection (1%)
- Depression (1%)
- Rhinitis (4%)
- Cough (4%)
- Pharyngitis (4%)
- Viral infection (2%)
Hydrochlorothiazide
- Anorexia
- Epigastric distress
- Hypotension
- Orthostatic hypotension
- Photosensitivity
- Anaphylaxis
- Anemia
- Confusion
- Erythema multiforme
- Stevens-Johnson syndrome
- Exfoliative dermatitis including toxic epidermal necrolysis
- Dizziness
- Hypokalemia and/or hypomagnesemia
- Hyperuricemia
- Headache
Warnings
Acute transient myopia and acute angle-closure glaucoma has been reported, particularly with history of sulfonamide or penicillin allergy (hydrochlorothiazide is a sulfonamide)
Not for initial treatment
Electrolyte disturbances may occur
Hyperkalemia, particularly when coadministered with potassium-sparing diuretics, potassium supplements, or salt substitutes; concurrent therapy with hydrochlorothiazide may reduce the frequency of this effect
Photosensitivity may occur
Hypotension may occur in patients who are salt or volume depleted (correct the volume depletion especially in patients receiving high dose diuretics)
Dual blockade of the renin angiotensin system with ARBs, ACE inhibitors, or aliskiren associated with increased risk for renal function changes (including acute renal failure) compared to monotherapy
Caution in aortic mitral stenosis, hepatic impairment, hypercholesterolemia, hypercalcemia, parathyroid disease, pre-existing renal insufficiency, systemic lupus erythematosus, bilateral renal artery stenosis or anuria
Hydrochlorothiazide may alter glucose tolerance and raise serum levels of cholesterol and triglycerides
Thiazides may decrease urinary calcium excretion
Pregnancy and Lactation
Pregnancy Category: C (1st trimester); D (2nd & 3rd trimesters)
Lactation: excretion in milk unknown/not recommended
Maximum Dosage
900 mg/day PO eprosartan and 25 mg/day PO hydrochlorothiazide.
900 mg/day PO eprosartan and 25 mg/day PO hydrochlorothiazide.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
How supplied
eprosartan/hydrochlorothiazide
tablet
- 600mg/12.5mg
- 600mg/25mg